Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis

Movement Disorders

Volumn 17, Issue 3, 2002, Pages 614-615

  Chatterjee, Anjan ^a   Louis, Elan D ^a,b   Frucht, Steven ^a  

^a Columbia University ^*  (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; PHENYTOIN;

ADULT; AGRANULOCYTOSIS; ARTICLE; CASE REPORT; CHOREOATHETOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; GINGIVA HYPERTROPHY; HEART PALPITATION; HUMAN; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTICONVULSANTS; ATHETOSIS; CHOREA; FEMALE; HUMANS; PIRACETAM; TREATMENT OUTCOME;

EID: 0036589934     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10118     Document Type: Article

References (12)

1. Fahn S. The paroxysmal dyskinesias. In: Marsden CD, Fahn S, editors. Movement Disorders 3. Oxford, UK: Butterworth-Heinnemann; 1994. p 310-345.
2. Mount LA, Reback S. Familial paroxysmal choreoathetosis. Arch Neurol Psychiatry 1940;44:841-847.
3. Kertesz A. Paroxysmal kinesiogenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases including one autopsied. Neurology 1967;17:680-690.
4. Bhatia KP. Familial paroxysmal dyskinesias: an update. Semin Neurol 2001;21:69-74.
5. Wein T, Andermann F, Silver K, Dubeau F, Andermann E, Forke-Frew F, Keene D. Exquisite sensitivity of paroxysmal kinesiogenic choreoathetosis to carbamazepine. Neurology 1996;47:1104-1106.
6. Kato M, Araki S. Paroxysmal kinesiogenic choreoathetosis. Report of a case relieved by carbamazepine. Arch Neurol 1969;20:508-513.
7. Przuntek H, Monninger P. Therapeutic aspects of kinesiogenic paroxysmal choreoathetosis of the Mount and Reback type. J Neurol 1983;230:163-169.
8. Dooley M, Plosker GL. Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 2000;60: 871-893.
9. Noyer M, Gillard M, Matagne A, Henichart JP, Wulfert E. The novel antiepileptic drug levetiracetam (ucbL059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995; 286:137-146.
10. Margineanu G, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 2000;42:281-285.
11. Frucht S, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112-1114.
12. Jain KK. An assessment of levetiracetam as an antiepileptic drug. Expert Opin Investig Drugs 2000;9:1611-1624.